Bioarctic (BIOA-B.ST) traded down -0.46 % during a 24 hours period ending at 10:08 PM Central Europe on Monday 26th. One Bioarctic stock can currently be bought for about SEK 308.2 on popular exchanges. Current supply of Bioarctic stocks is 88.7 mn. Bioarctic has a current market capitalization of SEK 26.6 bn and approximately SEK 24.2 mn worth of Bioarctic was traded on exchanges in the last 24 hours. Since last month end, Bioarctic has traded -5.78 % down. Simple moving average of last 200 days is at SEK 317.35. The highest price of past 52 weeks was recorded at SEK 364.4 on 02/18/2026. 52 weeks low was at SEK 257 on 11/11/2025.
Here is how related stocks have performed in the past 24 hours:
Asker Healthcare (ASKER.ST) traded up 1.75 % and now trades at SEK 71.5. Current market capitalisation for Asker Healthcare is SEK 27.9 bn.
Clas Ohlson -B (CLAS-B.ST) traded up 1.05 % and now trades at SEK 489. Current market capitalisation for Clas Ohlson -B is SEK 30.5 bn. Current price/earnings ratio for Clas Ohlson -B is 24.25.
Bufab (BUFAB.ST) traded down -2.93 % and now trades at SEK 133.2. Bufab has a market capitalisation of SEK 25.2 bn. Bufab has a current price to earnings ratio of 36.15.
Volvo Car (VOLCAR-B.ST) traded down -24.23 % and now trades at SEK 10.91. Volvo Car has a market capitalisation of SEK 31.7 bn. Volvo Car has a current price to earnings ratio of 4.48. Volvo Car AB reported its latest quarterly results on October 23, 2026, following the close of the quarter on September 30. The company posted a loss per share, a reversal from the prior quarter’s modest profit. Sales revenue declined significantly compared to the same period a year earlier, reflecting a notable contraction in the company’s top line. Analysts had anticipated a smaller loss and higher sales, but the actual figures fell short of expectations. The update underscores a challenging period for Volvo Car AB as it navigates a downturn in revenue and profitability.
Wallenstam -B (WALL-B.ST) traded up 0.79 % and now trades at SEK 38.2. Current market capitalisation for Wallenstam -B is SEK 24.2 bn. Current price/earnings ratio for Wallenstam -B is 8.28.
About Bioarctic
BioArctic AB is a research-intensive biopharmaceutical company based in Stockholm, Sweden, that specializes in developing disease-modifying treatments and diagnostics for neurodegenerative diseases. The company’s product BAN2401, a humanized monoclonal antibody, is currently in Phase 2b clinical trials targeting toxic amyloid-beta oligomers/protofibrils in Alzheimer’s disease and is also in preclinical trials for treating Down’s syndrome with dementia/traumatic brain injury. Additionally, BAN2401 Back-up is a disease-modifying antibody treatment in the late preclinical phase for patients with early Alzheimer’s disease. BioArctic AB also develops AE1501, AD1502, and AD1503 disease-modifying treatments for prodromal and mild Alzheimer’s disease; BAN0805, an anti-alpha-synuclein for treating Parkinson’s disease; and SC0806, a biodegradable device in Phase 1/2 clinical trial for complete spinal cord injuries. The company also works on imaging and biochemical biomarkers for treating Alzheimer’s disease; imaging and biochemical biomarkers for Parkinson’s disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier. BioArctic AB has collaborations with Eisai Co., Ltd. and AbbVie Inc.; and a research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop diagnostic methods for Alzheimer’s disease. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB was founded in 1992 and is headquartered in Stockholm, Sweden.